2023
Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).
Couvillon A, Turkbey B, Choyke P, Lee-Wisdom K, McKinney Y, Sidlow R, Mullane M, Giri V, Morgan T, Cheng H, Merino M, Figg W, Pinto P, Dahut W, Karzai F. Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI). Journal Of Clinical Oncology 2023, 41: 390-390. DOI: 10.1200/jco.2023.41.6_suppl.390.Peer-Reviewed Original ResearchGermline pathogenic variantsProstate cancerActive surveillancePathogenic variantsMedian ageRadiation therapyMonitoring of PCaDiagnosis of PCaDistinct pathogenic variantsHigh-risk geneticsPIRADS 3 lesionsPIRADS 4 lesionsISUP grade group 1Grade group 1Localized prostate cancerMonoallelic pathogenic variantsDNA mismatch repair genesLikely pathogenic variantsProstate cancer diagnosisMismatch repair genesDefinitive treatmentPSA monitoringProstate biopsyBiopsy specimensRisk factors
2017
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal Of Clinical Oncology 2017, 36: jco.2017.74.117. PMID: 29236593, PMCID: PMC6075860, DOI: 10.1200/jco.2017.74.1173.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProstate cancerGenetic testingMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAggressive prostate cancerProstate cancer riskGenetic counselingMultidisciplinary consensus statementDNA mismatch repair genesExpert consensus conferenceFamilial prostate cancerHereditary prostate cancerClinical genetic testingMismatch repair genesMetastatic settingPCa managementLynch syndromeOvarian cancerBRCA2 mutationsConsensus statementFamily historyCancer riskHeterogeneous diseaseConsensus conferenceComprehensive genetic evaluation